INTRODUCTION
Despite advances in bioengineering and the widespread use of antibiotic prophylaxis, medical implant infections represent a significant source of morbidity in the United States [1] . Two of the most common causative agents of perioperative infections are
Staphylococcus aureus and coagulase-negative staphylococci (CoNS), in particular S.
epidermidis [1] . Both species are frequent commensal organisms of the human skin, and insertion of medical implants through the skin may result in the colonization of these devices. Attached to the surface of the implant, bacteria aggregate in a hydrated polymeric matrix forming sessile communities of biofilm, well protected against hostile conditions of the environment, including antimicrobial exposure [2, 3] .
Staphylococci spp., especially multidrugresistant Staphylococci spp. organized in biofilm, represent a significant challenge for clinicians making it difficult or impossible to treat with antimicrobial agents, and detachment from the device may result in systemic infections [4] . Daptomycin (DAP) is a potent lipopeptide that has demonstrated rapid and concentration-dependent bactericidal activity against Staphylococci spp. [5] . Although DAP is known to rapidly penetrate the matrix of biofilm, little is known about the pharmacodynamic activity of DAP in biofilmassociated infections to explain the observed reduced bactericidal activity [6] . [11, 12] . Even in strains with diminished susceptibility, CLA has been shown to eradicate the polysaccharide glycocalyx matrix surrounding MRSA and S. epidermidis bacterial colonies, subsequently decreasing biofilm formation and increasing drug penetration [11, 13, 14] .
The objective of the present study was to quantify the ability of S. aureus and S. 
MATERIALS AND METHODS

Bacterial Strains
Two MRSA (R5266 and R3640), including 1 hVISA (R3640) confirmed by population analysis, and 1 MRSE (R461) were selected from the Anti-Infective Research Laboratory collection to be evaluated.
Antimicrobials
Daptomycin analytical powder was provided by the manufacturer (Cubist Pharmaceuticals, Inc., Lexington, MA, USA [15] . Biofilm MICs (MBIC) of all antimicrobials were performed using the pinlid method as previously described [16] . Drugcontaining plates at threefold the organism MIC were used to screen for changes in susceptibility.
In Vitro PK/PD Model
Isolates were grown on TSA plates incubated at 37°C for 24 h and then suspended in normal saline to reach a concentration equivalent to a 0.5 McFarland. The in vitro model consisted of a previously described CDC biofilm reactor (CBR) model (BioSurfaces Technologies, Bozeman, MT, USA), which we modified to run PK/PD, simulating human PK to evaluate the in vitro activity of antimicrobials [11, 17, 18] . Briefly, a 40-h biofilm conditioning phase was performed prior to drug therapy initiation and consisted of a 24 h incubation at 37°C in 1% gSTSB inoculated with the specified organism, followed by 16 
Biofilm Quantification
Capacity of organisms to form biofilm was assessed by the crystal violet method as previously described [32, 33] . Bacterial strains were grown in 96-well polystyrene flat bottom trays for 24 h using gSTSB, 2% NaCl and 50 mg/ L calcium. After incubation, the broth containing free planktonic cells was drained, washed with normal saline and each well was stained with 2% crystal violet, rinsed with deionized water and dried. Following drying, 33% (vol/vol) glacial acetic acid was added to resolubilize the dye and break down the biofilm for reading. Adherent presence of biofilm was measured at optical density (OD) 570 using a spectrophotometer. Control strains for low, medium and high biofilm production in this assay were ATCC 12228, 35556 and NRS 101, respectively.
Scanning Electron Microscopy (SEM)
Coupons from rods recovered at 0 and 72 h were evaluated for presence and structure of biofilm by SEM. After removal, coupons were rinsed in normal saline to remove non-adherent cells and immersed in a fixative solution containing 2.5% glutaraldehyde and 2% paraformaldehyde in 0.1 M sodium phosphate buffer. Coupons were then dehydrated in a graded ethanol series and carbon coated at 30 A for 3 min utilizing a SeeVac Conductavac IV sputter coater (Seevac Inc., Pittsburgh, PA, USA). The coupons were imaged using a Hitachi S570 SEM at 2,0009 magnification and evaluated for the presence and characteristics of biofilm.
Statistical Analysis
Changes in CFU/mL for planktonic and CFU/ cm 2 for biofilm-embedded bacteria at 72 h were compared by one-way analysis of variance (ANOVA) with Tukey's Post Hoc test. A P value of B0.05 was considered significant. All statistical analyses were performed using SPSS Statistical Software (Release 20.0, SPSS Inc., Chicago, IL, USA).
Compliance with Ethics
This article does not involve any new studies with human or animal subjects performed by any of the authors.
RESULTS
Organism susceptibilities are displayed in Table 1 In contrast, all strains were resistant to CLA (MIC[32 mg/L). MBICs for all isolates against were two-to four-fold higher than reported
MICs. Changes in organism susceptibilities post model experiments are reported in Table 2 .
All strains produced biofilm. MRSA 5266 biofilm production was similar to the low biofilm control strain 12228, while hVISA 3640 produced 50% more than control strain 12228 and 40% more than MRSA 5266. The CoNS strain (MRSA 461) produced the highest amounts of biofilm with 75 and 50% higher biofilm production compared to 5266 and 3640, respectively, and quantification most comparable to the medium producing control strain 35556.
The in vitro PK/PD model activities of antimicrobials are displayed in Table 2 and Table 2 ). These reductions were visible on SEM for MRSE 461 displaying fewer cells on TE coupons after therapy with DAP and RIF at 72 h (Fig. 2a) . Table 2 In vitro activity of antimicrobials in the pharmacokinetic/pharmacodynamic biofilm reactor model 
DISCUSSION
Biofilm infections involving S. aureus and S.
epidermidis are associated with poor patient [27] . However, these guidelines point out the research gap in alternatives to VAN for management of MRSA and CoNS infection [35] . RIF has been previously used in osteomyelitis and implant-related infection models and has demonstrated activity against staphylococcal biofilms [36] [37] [38] . Combination therapy with RIF is recommended for RIF-susceptible joint infections associated with biofilm formation, however, monotherapy is discouraged due to the high rate emergence of resistance. When used in combination with DAP, increased killing has been observed as well as a reduction in the emergence of RIF or DAP resistance [6, 27, 36, 39, 40] . However, the guidelines fail to specify which antibiotics are most advantageous to eradicate biofilm infection in combination with RIF. Medical devices are constructed from a variety of biomaterials that include polycarbonate, polyurethane, polystyrene, TE, ST and TT that are widely used in osteoarticular prostheses, fixation devices, pacemakers, prosthetic heart valves and vascular grafts [41, 42] . Therefore, it is important to explore the potential of antibiotics used alone and in combination against organisms that are frequently associated with biofilms affecting these materials.
In the current study, we evaluated the killing activity of DAP and VAN against more difficult to eradicate organisms grown on TT, TE and ST materials. As the results indicate, the addition of RIF to DAP and VAN expedited the elimination of biofilm-embedded organisms. The most potent activity was observed with the combination of DAP and RIF in all three organisms, followed by VAN plus RIF. The most profound effect was seen against MRSA, followed by hVISA and CoNS. Vancomycin has shown varied efficacy in eradication of biofilm infections [43, 44] .
Treatment outcomes may vary based on biofilm production and limited VAN penetration into the biofilm matrix [44] . Highdose DAP alone or in combination with RIF has been shown to have an increased effect and to decrease the emergence of resistance in in vitro and in vivo infection models [7, 11, 38] . We have previously demonstrated sustained bactericidal activity in in vitro models utilizing high-dose DAP in combination with CLA against biofilm-embedded MSSA [11] . DAP with RIF displayed similar bacterial eradication against a highly DAP-susceptible MRSA strain against biofilm-embedded bacteria grown on polycarbonate and also prevented the emergence of resistance [11] . DAP nonsusceptibility has been associated with medical device infections, specifically the monotherapy dose of 6 mg/kg/day has been less effective in eradicating adherent organisms [38, 39, 45] . In the current experiment, increasing the dose to 12 mg/kg daily of DAP prevented emergence of non-susceptible mutants in the hVISA strain, therefore, increased dosages may be necessary to eradicate organisms recovered from biofilm and prevent further resistance from occurring. The relatively high rate of emergence of resistance to RIF is consistent with prior data [11, 27, 28, 37] . The mechanism of resistance is not well understood, however, rpoB gene mutations and efflux mechanisms are thought to contribute [46] . Development of RIF resistance has previously been observed when used as monotherapy in a catheter-lock model [7] . DAP has been shown to reverse RIF resistance in VAN-resistant Enterococcus faecium. The mechanism is thought to be through potentiating RIF binding to RNA polymerase by increased permeabilization of the outer membrane [46, 47] . In MRSA implant infection models, a reduced incidence of RIF resistance has been found in the presence of DAP [48] . Of note, the addition of RIF prevented development of non-susceptibility to DAP in all isolates evaluated in our study. This finding is consistent with other foreign-body infection [36, 38] . Interestingly, MRSE displayed a higher proclivity toward development of RIF resistance compared to the hVISA and MRSA isolates, although DAP nonsusceptibility was more common in the latter two organisms. 
